𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bone mineral density (BMD) in patients with lymphoma: The effects of chemotherapy, intermittent corticosteroids and premature menopause

✍ Scribed by Dr Marcia A. Ratcliffe; Susan A. Lanham; David M. Reid; Audrey A. Dawson


Publisher
John Wiley and Sons
Year
1992
Tongue
English
Weight
441 KB
Volume
10
Category
Article
ISSN
0278-0232

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Young women with a chemotherapy‐induced early menopause are theoretically at considerable risk of developing post‐menopausal osteoporosis with problems developing earlier and more severely. In this study bone mineral density (BMD) measurements were made, using a dual‐energy X‐ray absorptiometer (DXA), at the spine and hip of 50 young women who had been treated for lymphoma, 24 of whom were post‐menopausal and 78, healthy age‐matched controls. On analysis of the results, there was no significant difference between the control group and the 26 post‐treatment, pre‐menopausal patients, but the BMD levels were significantly lower than the controls in the post‐menopausal group particularly in 16 patients who had been menopausal greater than 18 months. The results confirm that these young women with treatment‐induced premature menopause are at considerable risk of developing osteoporotic problems. Early recognition of this is important so that preventative measures with hormone replacement therapy can be initiated where this is safely possible. The results also indicate that chemotherapy for lymphoma (cytotoxics and high dose intermittent steroids), are unlikely to contribute directly to the lowering of the BMD of these patients.


📜 SIMILAR VOLUMES


Osteonecrosis of the femoral head in pat
✍ Daniel C. Ihde; Vincent T. Devita 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB 👁 2 views

Four adult patients with malignant lymphoma were treated with combination chemotherapy including an alkylating agent, vincristine, procarbazine (in all but one case), and intermittent high-dose prednisone. Twenty to 42 months after initiation of therapy, osteonecrosis of the femoral head developed.